drugset
drugset / Trial / NCT05413915

Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

NCT05413915 ↗

Phase 3 Terminated 8 enrolled Sarit Assouline Novartis · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to establish if consolidation of imatinib-treated patients in stable DMR through the addition of asciminib, can lead to superior rates of TFR1, compared to imatinib alone in Chronic Phase-Chronic Myelogenous Leukemia patients.

Timeline

Start
2023-11-01
Primary completion
2025-07-02
Completion
2025-07-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Asciminib Unknown 60 mg Oral
Subject Imatinib Small molecule 300 mg Oral
Subject Imatinib Small molecule 400 mg Oral

Indications

chronic myeloid leukemia